Medication info

DROVAN (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Korea PMG Pharmaceutical Co., Ltd.
Appearance
A colorless and transparent solution contained in a colorless and transparent glass prefilled syringe with an attached single-use needle.
Packaging
3 milliliters/prefilled syringe
Approval status
Active

MFDS item code 202001112 · Notified 2020.02.18 · Insurance code 697100921

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3 mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3 mg/dL) or less or whose creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3 mg/dL) or whose creatinine clearance is less than 30 mL/min, as clinical experience is insufficient. Older adults No dose adjustment is necessary.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
Korea PMG Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis that can occur in postmenopausal women. Osteoporosis is a condition where bones become weak and are more likely to break, which frequently occurs in postmenopausal women. This medication helps increase bone density and reduce the risk of fractures, thereby helping to effectively manage osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3 mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals thereafter. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3 mg/dL) or less or whose creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3 mg/dL) or whose creatinine clearance is less than 30 mL/min, as clinical experience is insufficient. Older adults No dose adjustment is necessary.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This medication must only be administered by intravenous injection, and caution is necessary because incorrect injection around arteries or veins can cause tissue damage. It should not be used in patients with allergies to this medication or its ingredients, or in patients with untreated hypocalcemia. During the use of this medication, various side effects such as gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, muscle pain, joint pain, fatigue, headache, rash, etc., may occur, but most are mild to moderate and not severe enough to require discontinuation of treatment. Rarely, osteonecrosis of the jaw, external auditory canal osteonecrosis, serious allergic reactions, ocular inflammation, atypical fractures, etc., have been reported, necessitating caution. Patients requiring dental treatment should undergo oral examination before administration and avoid excessive dental procedures while receiving this medication. This medication can temporarily lower blood calcium levels, so it is important to treat hypocalcemia and bone and mineral metabolism disorders before administration and to ensure sufficient intake of calcium and vitamin D. Patients with impaired kidney function or those taking medications that may affect the kidneys require regular monitoring and examination. Pregnant or breastfeeding women are advised not to use this medication due to the lack of safety confirmation. In cases of overdose, there may be toxicity to the kidneys and liver, which requires careful monitoring and appropriate treatment. This medication should not be mixed with calcium-containing solutions or other intravenous medications and must be administered solely by intravenous injection. Do not reuse the needle and syringe after use; dispose of them safely.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, influenza-like illnesses, fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling, edema, urticaria, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical digital fractures, intertrochanteric femur fractures, osteonecrosis of the external auditory canal, osteonecrosis of the jaw, dizziness, hypothyroidism, peripheral motor neuropathy, hearing loss, dyspnea, skin desquamation, multiple organ failure, death, optic atrophy, lower motor neuron lesions, tremor, gastrointestinal disorders unspecified, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, laryngitis, vaginitis, menopausal symptoms, insomnia, anxiety, tinnitus, lipoma, ocular hemorrhage, heart failure, urination disorders, hematuria, sensory loss, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

A colorless and transparent solution contained in a colorless and transparent glass prefilled syringe with an attached single-use needle.

Package unit

3 milliliters/prefilled syringe

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.